WAVE Clinical trials

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Published September 03, 2025 at 11:30 AM

(NASDAQ:WAVE) Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT)

Related Questions

How will the positive RestorAATion-2 trial update influence WAVE's near‑term share price and trading volume? What does the achieved serum AAT protein level mean relative to existing therapies for Alpha‑1 Antitrypsin deficiency? What are the projected milestones and timeline for FDA approval and commercialization following this trial result?

Find similar articles on Candlesense globenewswire